MedTrace Logo

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT04886284 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-11

No results posted yet for this study

Summary

There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Conditions

  • Staphylococcus Aureus Bacteremia
  • Staphylococcus Aureus Septicemia
  • Staphylococcal Sepsis
  • Staphylococcus Aureus Endocarditis

Interventions

DRUG

Ertapenem

Adjunctive ertapenem

DRUG

Placebo

Saline placebo

Sponsors & Collaborators

  • Todd C. Lee MD MPH FIDSA

    lead OTHER

Principal Investigators

  • Todd C Lee, MD MPH FIDSA · Research Institute of the McGill University Health Centre

  • Emily G McDonald, MD MSc · Research Institute of the McGill University Health Centre

  • Matthew P Cheng, MD · Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2027-04-30
Completion
2027-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04886284 on ClinicalTrials.gov